Cognition Therapeutics presents new data at CTAD conference

Cognition Therapeutics announced upcoming presentations from studies of CT1812, the Company’s lead candidate for the treatment of adults with early, mild and moderate Alzheimer’s disease at the Clinical Trials on Alzheimer’s Disease, CTAD, conference being held October 24-27, 2023 virtually and in person in Boston, MA. An oral late-breaking presentation will also discuss the Phase 2 study design of the company’s ongoing START study, which is enrolling adults with early Alzheimer’s disease. Participants in START will be permitted to be on stable background therapy with lecanemab, an FDA-approved anti-amyloid antibody. “The approval of monoclonal antibody therapies against amyloid beta protofibrils represents an important milestone in Alzheimer’s drug development, but industry experts agree that combination treatments will likely be required to achieve greater impact on the disease,” explained Anthony Caggiano, MD, Ph.D., Cognition’s CMO and head of R&D. “To this end, we and our colleagues at the National Institute of Aging and the Alzheimer’s Clinical Trials Consortium made the strategic decision to allow participants to enroll in the ongoing Phase 2 START study who are being administered lecanemab. We believe this will allow us to assess the benefit of CT1812 in real-world conditions.”